No registrations found.
ID
NL-OMON29441
Source
NTR
Brief title
DELTa S
Health condition
Delirium treatment on a surgical ward.
Sponsors and support
Primary sponsor
:
trial medication sponsored by Novartis
Intervention
Outcome measures
Primary outcome
Length of delirium.
Secondary outcome
1. Length of stay hospital;
2. Severity of delirium;
3. Functional outcome 3,6,13 weeks after delirium;
4. Need of escape medication;
5. Cognition;
6. Adverse events.
Background summary
N/A
Study objective
Rivastigmine is as effective in the treatment of delirium as Haloperidol.
Study design
N/A
Intervention
Haloperidol or rivastigmine for the treatment of delirium.
Public
Jeroen Bosch Hospital, Department of Surgery,
P.O Box 90153
R.J.A. Wensen, van
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6992708
r.v.wensen@jbz.nl
P.O Box 90153
R.J.A. Wensen, van
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6992708
r.v.wensen@jbz.nl
Scientific
Jeroen Bosch Hospital, Department of Surgery,
P.O Box 90153
R.J.A. Wensen, van
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6992708
r.v.wensen@jbz.nl
P.O Box 90153
R.J.A. Wensen, van
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6992708
r.v.wensen@jbz.nl
Inclusion criteria
Patients with a fractured hip, admitted on a surgical ward.
Exclusion criteria
Already use of Haloperidol/Rivastigmine/Donepezil/Galantamine.
Design
Study type
:
Interventional
Intervention model
:
Other
Allocation
:
Randomized controlled trial
Masking
:
Double blinded (masking used)
Control
:
Placebo
Recruitment
NL
Recruitment status
:
Suspended
Start date (anticipated)
:
Enrollment
:
100
Type
:
Anticipated
Positive opinion
Date
:
Application type
:
First submission
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL495 |
| NTR-old | NTR537 |
| Other | : N/A |
| ISRCTN | Incomplete data for ISRCTN |
Summary results
N/A